Literature DB >> 21045268

Relation between development of cardiovascular disease and the C242T CYBA polymorphism of the NADPH oxidase in ESRD patients.

Feng-Ying Tang1, Ying Zhu, Gui Hua Wang, Xiong-Wei Xie.   

Abstract

BACKGROUND: The development of cardiovascular disease in ESRD patients is considered to be associated with oxidative stress. NAD(P)H oxidase has attracted attention as mechanisms of generating oxidative stress. We investigated the relation between the genotype of the C242T CYBA polymorphism of the NADPH oxidase and the development of cardiovascular disease in ESRD patients.
METHODS: A total of 289 ESRD patients were recruited and allocated to one of the two groups: patients without cardiovascular disease (group N; n=192) and patients developing cardiovascular disease (group D; n=97). The C242T CYBA polymorphism was determined by RFLP-PCR methods.
RESULTS: The frequency of the C242T CT+TT genotype was significantly lower in group D than in group N (9.1 vs. 20.2%). In multiple Logistic regression analysis, systolic blood pressure, smoking history and this gene polymorphism were shown to be independent variables for the development of cardiovascular disease in ESRD patients.
CONCLUSIONS: These results suggest that assessment of the C242T CYBA polymorphism of the NADPH oxidase may be useful in identifying the risk for developing cardiovascular disease in ESRD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045268      PMCID: PMC3835383          DOI: 10.3233/DMA-2010-0730

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  1 in total

1.  NADPH Oxidase Gene Polymorphism is Associated with Mortality and Cardiovascular Events in 7-Year Follow-Up.

Authors:  Milena Racis; Wojciech Sobiczewski; Anna Stanisławska-Sachadyn; Marcin Wirtwein; Elżbieta Bluj; Michał Nedoszytko; Joanna Borzyszkowska; Janusz Limon; Andrzej Rynkiewicz; Marcin Gruchała
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.